122 related articles for article (PubMed ID: 12761967)
1. [Expression and significance of serum soluble tumor necrosis factor receptor-I in patients with head and neck neoplasm].
Dong W; Xu J; Qiao Z; Wang N; Yu R
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Dec; 36(6):468-70. PubMed ID: 12761967
[TBL] [Abstract][Full Text] [Related]
2. [Estimation and clinical significance of serum soluble tumor necrosis factor receptors in patients with acute leukemia].
Lin M; Meng X
Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):245-8. PubMed ID: 11601213
[TBL] [Abstract][Full Text] [Related]
3. Detection of soluble tumor necrosis factor-p55 levels in the serum and ascitic fluid of patients with hepatocellular carcinoma.
Gao L; Bai L; Nan QZ; Yang XS; Chen K; Wen HP; Lai ZS; Bo L; Zhang YL; Zhang ZS
Di Yi Jun Yi Da Xue Xue Bao; 2002 Jul; 22(7):641-3. PubMed ID: 12376300
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
5. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
Kaneyama K; Segami N; Sun W; Sato J; Fujimura K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
[TBL] [Abstract][Full Text] [Related]
6. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study.
Burger RA; Darcy KM; DiSaia PJ; Monk BJ; Grosen EA; Gatanaga T; Granger GA; Wang J; Tian C; Hanjani P; Cohn DE
Cancer; 2004 Jul; 101(1):106-15. PubMed ID: 15221995
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
9. [Changes of serum soluble tumor necrosis factor receptor I in patients with rheumatic fever].
Chen CY; Yang ZC; Lian NW
Hunan Yi Ke Da Xue Xue Bao; 2001 Dec; 26(6):571-2. PubMed ID: 12536547
[TBL] [Abstract][Full Text] [Related]
10. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy.
Grosen EA; Granger GA; Gatanaga M; Ininns EK; Hwang C; DiSaia P; Berman M; Manetta A; Emma D; Gatanaga T
Gynecol Oncol; 1993 Jul; 50(1):68-77. PubMed ID: 8394276
[TBL] [Abstract][Full Text] [Related]
11. [Significance of platelet aggregation in patients with malignant tumor of the head and neck].
Nong HT
Zhonghua Zhong Liu Za Zhi; 1993 Nov; 15(6):454-7. PubMed ID: 8200287
[TBL] [Abstract][Full Text] [Related]
12. [The effect of the microenvironment of head and neck cancers on tumor progression].
Lukits J
Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
[TBL] [Abstract][Full Text] [Related]
13. Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer.
Muc-Wierzgon M; Nowakowska-Zajdel E; Zubelewicz B; Wierzgon J; Kokot T; Klakla K; Szkilnik R; Wiczkowski A
J Exp Clin Cancer Res; 2003 Jun; 22(2):171-8. PubMed ID: 12866566
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of sTNFR-1 and sFas in patients with relapsing-remitting multiple sclerosis.
Bilińska M; Frydecka I; Podemski R; Gruszka E
Med Sci Monit; 2002 Oct; 8(10):CR720-3. PubMed ID: 12388926
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of proinflammatory cytokine inhibitors (sTNFR I, sTNFR II, IL-1 ra), anti-inflammatory cytokines (IL-10, IL-13) and activation of neutrophils after burn-induced inflammation.
Sikora JP; Chlebna-Sokół D; Andrzejewska E; Chrul S; Polakowska E; Wysocka A; Sikora A
Scand J Immunol; 2008 Aug; 68(2):145-52. PubMed ID: 18702744
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of a 21-kDa protein in the circulation of tumor-bearing patients.
Shalitin C; Epelbaum R; Moskovitz B; Segal R; Valansi C; Werner M; Livne PM
Cancer Detect Prev; 1994; 18(5):357-65. PubMed ID: 7812982
[TBL] [Abstract][Full Text] [Related]
18. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
Caballero M; Grau JJ; Blanch JL; Domingo-Domenech J; Auge JM; Jimenez W; Bernal-Sprekelsen M
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1143-8. PubMed ID: 18025320
[TBL] [Abstract][Full Text] [Related]
19. Serum nitric oxide levels in patients with head and neck squamous cell carcinoma.
Kizilay A; Kalcioğlu MT; Ozuğurlu F; Ozyurt H; Aladağ I; Ozturan O; Akyol O
Kulak Burun Bogaz Ihtis Derg; 2007; 17(3):148-51. PubMed ID: 17873505
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer.
Andratschke M; Chaubal S; Pauli C; Mack B; Hagedorn H; Wollenberg B
Anticancer Res; 2005; 25(4):2821-6. PubMed ID: 16080532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
